280 related articles for article (PubMed ID: 23591953)
1. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.
Nanni C; Schiavina R; Boschi S; Ambrosini V; Pettinato C; Brunocilla E; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S11-7. PubMed ID: 23591953
[TBL] [Abstract][Full Text] [Related]
2. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.
Nanni C; Schiavina R; Brunocilla E; Borghesi M; Ambrosini V; Zanoni L; Gentile G; Vagnoni V; Romagnoli D; Martorana G; Fanti S
Clin Genitourin Cancer; 2014 Apr; 12(2):106-10. PubMed ID: 24135632
[TBL] [Abstract][Full Text] [Related]
3. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
5. First case of 18F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative 11C-choline PET/CT: new imaging techniques may expand pioneering approaches.
Schiavina R; Concetti S; Brunocilla E; Nanni C; Borghesi M; Gentile G; Cevenini M; Bianchi L; Molinaroli E; Fanti S; Martorana G
Urol Int; 2014; 92(2):242-5. PubMed ID: 24334968
[TBL] [Abstract][Full Text] [Related]
6. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
[TBL] [Abstract][Full Text] [Related]
7. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis.
Ren J; Yuan L; Wen G; Yang J
Acta Radiol; 2016 Apr; 57(4):487-93. PubMed ID: 25907118
[TBL] [Abstract][Full Text] [Related]
8. Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients.
Kairemo K; Rasulova N; Partanen K; Joensuu T
Biomed Res Int; 2014; 2014():305182. PubMed ID: 24991547
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer.
Michael J; Khandani AH; Basak R; Tan HJ; Royce TJ; Wallen E; Whang Y; Rose TL; Milowsky M; Bjurlin MA
Urology; 2021 Sep; 155():192-198. PubMed ID: 33516829
[TBL] [Abstract][Full Text] [Related]
10. The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.
Sathianathen NJ; Butaney M; Konety BR
World J Urol; 2019 Jul; 37(7):1239-1249. PubMed ID: 30003375
[TBL] [Abstract][Full Text] [Related]
11. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
[TBL] [Abstract][Full Text] [Related]
12. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option?
Nanni C; Schiavina R; Rubello D; Ambrosini V; Brunocilla E; Martorana G; Fanti S
Nucl Med Commun; 2013 Sep; 34(9):831-3. PubMed ID: 23887227
[No Abstract] [Full Text] [Related]
15. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
[TBL] [Abstract][Full Text] [Related]
17. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
[TBL] [Abstract][Full Text] [Related]
18. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
20. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques?
Schiavina R; Ceci F; Borghesi M; Brunocilla E; Vagnoni V; Gacci M; Castellucci P; Nanni C; Martorana G; Fanti S
Curr Radiopharm; 2013 Jun; 6(2):92-5. PubMed ID: 23597246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
